Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib with reinduction chemotherapy and maintenance in pediatric and young adult relapsed/refractory FLT3-ITD acute myeloid leukemia
MOH_2018-05-23_002264Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of quizartinib in acute myeloid leukemia (AML) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Safety, Pharmacokinetics and 3 more. Started May 2018; status: recruiting.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2018-05-23_002264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-23_002264.